A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)

Trial Profile

A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Therapeutic Use
  • Acronyms PIONEER-OLE
  • Sponsors AbbVie
  • Most Recent Events

    • 26 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 21 Jul 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Jul 2016.
    • 25 Jan 2016 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top